大行評級丨美銀:錦欣生殖受惠刺激政策 升目標價至3.5港元
美銀證券發表報吿,錦欣生殖(1951.HK)去年收入增長0.8%,純利下跌17.9%至2.83億元,焦點在於國家刺激政策,維持予“買入”評級,目標價由3港元上調至3.5港元。給予去年業績表現,美銀證券將錦欣生殖2025至2027年度的收入預測分別均下調12%。此外,又下調了今明兩年的毛利率預測,但從2028年起提高了長期毛利率,原因是更新了收入組合和海外業務的銷售增長。隨着深圳新醫院大樓的竣工,該行從2025年起降低了資本支出預測。美銀證券相信,錦欣生殖將受惠於最近的刺激政策,例如將體外受精(IVF)納入醫療保險和對中國新生兒的補貼。其在美國新簽約的17名醫生,為海外業務提供了明顯的增長可見性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.